Gastroesophageal reflux disease and its complications effect 40 % of the US population. It is the most common reason for outpatient GI visits with treatment costs amounting to nearly $10 billion a year. Thisissue updates interested physicians on the new advance in GERD pathogenesis, diagnosis and medical/surgical treatment , especially over the last 5 years. Lots of advancements have been made in this time period and this will be a excellent reference book for the busy academic and community physician interested in GERD.
Gastroesophageal reflux disease and its complications effect 40 % of the US population. It is the most common reason for outpatient GI visits with treatment costs amounting to nearly $10 billion a year. Thisissue updates interested physicians on the new advance in GERD pathogenesis, diagnosis and medical/surgical treatment , especially over the last 5 years. Lots of advancements have been made in this time period and this will be a excellent reference book for the busy academic and community physician interested in GERD. "The data summarized in a concise manner in this book gives an excellent tool for clinical practice in order to establish a precise diagnosis, appropriate investigation procedures and an adequate therapy in GERD patients." Reviewed by: Ciobanu Lidia, Bogdan Furnea, Cluj-Napoca, Romania on behalf of The Journal of Gastrointestinal and Liver Diseases, June 2014
This issue will be an informative treatise on gastroparesis, a symptomatic chronic disorder of the stomach characterized by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis is an increasingly recognized and diagnosed disorder. Treatment can be challenging due to several mechanisms which play a role in causing the symptoms. Symptoms of gastroparesis are variable and include early satiety, nausea, vomiting, bloating, and upper abdominal discomfort. These symptoms can range from mild to severe leading to such complications as malnutrition, functional disability, and multiple hospitalizations. The three most common etiologies are diabetes, post-surgical, and idiopathic (unknown). Treatment consists of dietary manipulation, medical, and surgical therapy. The articles will provide a comprehensive review and in-depth information on gastroparesis. Each chapter will be written by an expert in the area. This issue will give the reader a better appreciation for the breadth of gastroparesis.
A thorough update is presented by the Guest Editors on the diagnosis, treatment, and management of Barrett’s Esophagus. Not only do they address the most pertinent clinical issues like screening, biomarkers, surveillance, therapeutics, and predictors of disease progression but they present state of the art material on therapeutic/treatment modalities like EMR, ESD, and ablative therapy. Further, articles are presented on epidemiology, molecular pathogensis, and cost-analysis studies so that the reader will come away with a comprehensive update on Barrett’s Esophagus.
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
Ikuo Hirano, an international leader and pioneer in EoE, has assembled well-recognized experts in the field to provide a state-of-the-art, practical understanding of EoE for both children and adults in 2014. Topics you will find in this issue of Gastroenterology Clinics of North America include the epidemiology, clinical presentation, diagnosis, and management of EoE as well as a glimpse into what the future holds. In addition, articles dedicated to mechanisms of disease pathogenesis and complications complete this comprehensive assessment of the field at present.The Editors believe that this issue will enhance your understanding of EoE.
Together with Consulting Editor, Dr. Alan Buchman, Dr. Parkman has created as state-of-the-art issue devoted to the modern technology and approaches for evaluation and treatment of GI motility. He has provided coverage for the esophagus, colon, small intestine, and gut. Leaders in the field have contributed the detailed clinical review articles on the following topics: Enhancing High Resolution Esophageal Manometry: Use of Impedance, multiple rapid swallows, Position change, Solid food boluses, and other techniques; EndoFLIP in the esophagus: Assessing sphincter function, wall stiffness, motility to guide treatments; Evaluation and Treatment of patients with persistent reflux symptoms despite PPI treatment; Esophageal Evaluation for Patients undergoing Lung Transplant Evaluation: What should we do for evaluation and management; Tailoring Endoscopic and Surgical Treatments for GERD; Endoscopic and Surgical Treatments for Achalasia: Who to treat and how; Enhancing Scintigraphy for evaluation of gastric, small bowel, colonic motility; Targeting treatment for gastroparesis: Use of clinical tests to guide treatments; Endoscopic and Surgical Treatments for Gastroparesis: What to do and Whom to treat; Gastric Biopsies in Gastroparesis: Insights to Gastric Neuromuscular Disorders to Help with treatment; SIBO: How to diagnose and treat (and then treat again); Assessing anorectal function in constipation and fecal incontinence; Treating chronic abdominal pain in patients with Chronic Recurrent Abdominal Pain and IBS; and Refractory Chronic Constipation: How to evaluate and treat. Gastroenterologists will come away with the technical information they need to improve outcomes in their patients.
With collaboration of Consulting Editor, Dr. Alan Buchman, Guest Editors Drs. Gerard Mullen and Berkeley Limketkai have created a practical and current issue covering the breadth of topics in nutrition and gastrointestinal disease. Articles are specifically devoted to the following topics: Nutrition in the Management of Inflammatory Bowel Diseases; Irritable Bowel Syndrome: Food as a Friend or Foe; Treatment of Obesity: Beyond the Diet; Nutritional Management of Acute Pancreatitis; Nutritional Care in Patients with Intestinal Failure; The Life-long Role of Nutrition on the Gut Microbiome and Gastrointestinal Disease; Nutritional Strategies for Esophageal Disorders; Precision Medicine in Obesity; Gastrointestinal Food Allergies and Intolerances; All Things Gluten; Fish Oil for Inflammatory Bowel Disease: Panacea or Placebo; Nutrition Tools for the Practicing Gastroenterologist; Colorectal Cancer and Diet: Is Diet an Intervention; Non-Alcoholic Fatty Liver Disease: Nutritional Considerations; and Nutritional Considerations in the Hospital Setting. Readers will come away with current clinical information that they can employ in the clinical setting to improve outcomes in patients with gastrointestinal diseases.
The goal of this issue of Gastroenterology Clinics is to present GI diseases which affect women uniquely, such as pelvic floor problems and pregnancy related disorders, or which require a more considered approach such as functional bowel disease or autoimmune processes. It will also address the position of women and female gastroenterologists in the health system as a whole. This issue is published at an exciting, transitional time in the future of gastroenterology, as we adjust approaches for the assessment of disease in a large portion of our patient population, and as we address the challenges in practicing medicine based on the uniqueness of specific populations.
